Patients with Advanced Ovarian Cancer Seen to Benefit from Oral Therapy in Phase 2 Trial

Patients with Advanced Ovarian Cancer Seen to Benefit from Oral Therapy in Phase 2 Trial
Ovarian cancer patients who are refractory to platinum-based chemotherapy may significantly benefit from the investigative treatment selinexor, according to the results of a Phase 2 clinical trial recently presented at the European Society for Medical Oncology (ESMO) 2016 Congress, held in Copenhagen. The trial also showed promising response rates in patients with endometrial cancer who had received

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *